Meta-analysis confirms benefits of rimegepant in episodic migraine

Key clinical point: Meta-analysis confirmed better therapeutic efficacy of rimegepant compared with placebo in patients with episodic migraine (EM), along with no significant difference in adverse events.

Major finding: Rimegepant was more effective than placebo in terms of achieving pain freedom and pain relief at 2 hours (odds ratio [OR] 1.84 and 1.80, respectively), 2-24 hours (OR 2.44 and 2.10, respectively), and 2-48 hours (OR 2.27 and 1.92, respectively; all P < .00001) post-dose. The occurrence of adverse events was not significantly different between the rimegepant and control arms (P = .06).

Study details: The data come from a systematic review and meta-analysis of 4 randomized controlled trials including 4230 patients with EM.

,

Disclosures: This study did not declare the source of funding. The authors declared no conflicts of interest.

Source: Wang Q et al. Clinical efficacy and safety of rimegepant in the treatment of migraine: A meta-analysis of randomized controlled trials. Front Neurol. 2023;14:1205778 (Jun 20). Doi: 10.3389/fneur.2023.1205778